このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Beam Therapeutics 将来の成長
Future 基準チェック /06
Beam Therapeuticsの収益と利益は、それぞれ年間31.4%と14.3%減少すると予測されています。EPS は年間11.6%で 減少すると予想されています。自己資本利益率は 3 年後に-71.5%になると予測されています。
主要情報
-14.3%
収益成長率
-11.6%
EPS成長率
| Biotechs 収益成長 | 24.7% |
| 収益成長率 | -31.4% |
| 将来の株主資本利益率 | -71.5% |
| アナリストカバレッジ | Good |
| 最終更新日 | 21 Jun 2024 |
今後の成長に関する最新情報
Recent updates
We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn
May 13
Beam Therapeutics: A 'Hold' Amid High Valuation And Uncertain Revenue Prospects
Apr 24Lacklustre Performance Is Driving Beam Therapeutics Inc.'s (NASDAQ:BEAM) Low P/S
Apr 07Beam Therapeutics Inc. (NASDAQ:BEAM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 01Things Look Grim For Beam Therapeutics Inc. (NASDAQ:BEAM) After Today's Downgrade
Feb 29Beam Therapeutics: Cool Tech, But At A Way Inflated Price For Now
Feb 08This Just In: Analysts Are Boosting Their Beam Therapeutics Inc. (NASDAQ:BEAM) Outlook for This Year
Nov 01We're Hopeful That Beam Therapeutics (NASDAQ:BEAM) Will Use Its Cash Wisely
Jul 23Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation
Apr 08Industry Analysts Just Made A Massive Upgrade To Their Beam Therapeutics Inc. (NASDAQ:BEAM) Revenue Forecasts
Nov 08Beam Therapeutics: Now Is Not The Right Time To Own
Sep 15Beam Therapeutics GAAP EPS of -$1.02 misses by $0.05, revenue of $16.65M beats by $7.21M
Aug 09Beam drops 19% as FDA issues clinical hold on blood cancer candidate
Aug 01Revisiting Beam Therapeutics Among Collaborative Catalysts
Jul 10Newsflash: Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Have Been Trimming Their Revenue Forecasts
May 10Beam Therapeutics Worth Watching Because Of Pfizer Interest?
Apr 21Beam Therapeutics: Getting More And More Interesting
Apr 10Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Mar 03Some Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Just Made A Major Cut To Next Year's Estimates
Mar 02Pfizer's Partnership With Beam Therapeutics About Becoming Global Leader In mRNA/Gene Therapy
Jan 19Beam Therapeutics: An Early Company In A Promising Field
Dec 27Beam Therapeutics: Recent Selling Pressure Leaves Behind A CRISPR Buying Opportunity
Dec 20Beam Therapeutics: This Technology Should Be Part Of Every Investor's Portfolio
Oct 01Beam Therapeutics: If You Buy Into The Technology, Buy Into The Stock
Aug 25業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 12/31/2026 | 59 | -454 | -326 | -295 | 6 |
| 12/31/2025 | 52 | -432 | -372 | -357 | 13 |
| 12/31/2024 | 50 | -402 | -383 | -370 | 14 |
| 3/31/2024 | 361 | -135 | -169 | -139 | N/A |
| 12/31/2023 | 378 | -133 | -183 | -149 | N/A |
| 9/30/2023 | 82 | -314 | -392 | -353 | N/A |
| 6/30/2023 | 80 | -327 | -380 | -338 | N/A |
| 3/31/2023 | 77 | -316 | -353 | -306 | N/A |
| 12/31/2022 | 61 | -289 | -26 | 23 | N/A |
| 9/30/2022 | 92 | -315 | 39 | 94 | N/A |
| 6/30/2022 | 77 | -234 | 123 | 171 | N/A |
| 3/31/2022 | 60 | -238 | 148 | 191 | N/A |
| 12/31/2021 | 52 | -371 | -113 | -66 | N/A |
| 9/30/2021 | 1 | -401 | -134 | -92 | N/A |
| 6/30/2021 | 0 | -408 | -155 | -117 | N/A |
| 3/31/2021 | 0 | -366 | -132 | -107 | N/A |
| 12/31/2020 | 0 | -196 | -112 | -96 | N/A |
| 9/30/2020 | 0 | -132 | -100 | -89 | N/A |
| 6/30/2020 | 0 | -119 | -94 | -85 | N/A |
| 3/31/2020 | 0 | -106 | -87 | -74 | N/A |
| 12/31/2019 | 0 | -91 | -85 | -72 | N/A |
| 9/30/2019 | 0 | -86 | -79 | -57 | N/A |
| 6/30/2019 | 0 | -134 | -70 | -50 | N/A |
| 3/31/2019 | N/A | -124 | -57 | -42 | N/A |
| 12/31/2018 | N/A | -117 | -33 | -20 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: BEAM今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: BEAM今後 3 年間、利益が出ない状態が続くと予測されています。
高成長収益: BEAM今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: BEAMの収益は今後 3 年間で減少すると予想されています (年間-31.4% )。
高い収益成長: BEAMの収益は今後 3 年間で減少すると予測されています (年間-31.4% )。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: BEAM 3 年以内に赤字になると予測されています。